BioSniper
Patent Expiry

Patent/Exclusivity Expiry: KHAPZORY

March 25, 2039
Company
Inhibrx Biosciences, Inc. (INBX)
Drug
KHAPZORY

Other upcoming events for INBX

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First
May 1, 2029
Patent ExpiryPatent/Exclusivity Expiry: VYKOURA
Dec 23, 2044

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
INBX OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle